BG103417A - Кондензирани бициклични производни на пиримидина - Google Patents

Кондензирани бициклични производни на пиримидина

Info

Publication number
BG103417A
BG103417A BG103417A BG10341799A BG103417A BG 103417 A BG103417 A BG 103417A BG 103417 A BG103417 A BG 103417A BG 10341799 A BG10341799 A BG 10341799A BG 103417 A BG103417 A BG 103417A
Authority
BG
Bulgaria
Prior art keywords
bicyclic derivatives
condensed pyrimidine
pyrimidine bicyclic
compounds
relates
Prior art date
Application number
BG103417A
Other languages
English (en)
Inventor
Lee Arnold
Mikel MOYER
Susan Sobolov-Jaynes
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103417A publication Critical patent/BG103417A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Изобретението се отнася до съединения с формула, в която R1, R2 и Z имат значенията, посочени в описанието, и до техни фармацевтично приемливи соли. Изобретението се отнася също до фармацевтични състави, които съдържат съединенията, и до методи за тяхното използване при лечението на хиперпролиферативни заболявания, например рак.
BG103417A 1996-11-27 1999-05-20 Кондензирани бициклични производни на пиримидина BG103417A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09
PCT/IB1997/001393 WO1998023613A1 (en) 1996-11-27 1997-11-05 Fused bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BG103417A true BG103417A (bg) 2000-06-30

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103417A BG103417A (bg) 1996-11-27 1999-05-20 Кондензирани бициклични производни на пиримидина

Country Status (24)

Country Link
US (1) US6413971B1 (bg)
EP (1) EP0946554A1 (bg)
JP (1) JP2000505109A (bg)
KR (1) KR20000057228A (bg)
CN (1) CN1237177A (bg)
AP (1) AP9701146A0 (bg)
AR (1) AR010740A1 (bg)
AU (1) AU4718997A (bg)
BG (1) BG103417A (bg)
BR (1) BR9713552A (bg)
CA (1) CA2272705C (bg)
CO (1) CO4650037A1 (bg)
HN (1) HN1997000146A (bg)
HR (1) HRP970641A2 (bg)
ID (1) ID18958A (bg)
IL (1) IL129825A0 (bg)
IS (1) IS5041A (bg)
MA (1) MA26452A1 (bg)
NO (1) NO992524L (bg)
OA (1) OA11051A (bg)
PA (1) PA8442001A1 (bg)
PE (1) PE17299A1 (bg)
TN (1) TNSN97192A1 (bg)
WO (1) WO1998023613A1 (bg)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027199A1 (en) * 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
JP4959049B2 (ja) 1997-08-22 2012-06-20 アストラゼネカ・ユーケイ・リミテッド 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR100415791B1 (ko) 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
BR0014843A (pt) 1999-10-19 2002-06-11 Merck & Co Inc Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
SK287401B6 (sk) 1999-11-05 2010-09-07 Astrazeneca Ab Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
EE05351B1 (et) 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
WO2001046196A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
CZ20023993A3 (cs) 2000-06-26 2004-02-18 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidinové sloučeniny jako imunosupresivní činidla
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
HU229471B1 (en) 2000-10-23 2014-01-28 Smithkline Beecham Corp 2,4,8-trisubstituted-8h-pyrido[2,3d]pyrimidine-7-one compounds, for the treatment of diseases mediated by csbp/p38 kinase
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005526714A (ja) * 2002-01-17 2005-09-08 ニューロジェン・コーポレーション カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
AU2003206068A1 (en) 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
KR20050086784A (ko) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
WO2004055004A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
WO2005023807A2 (en) * 2003-09-09 2005-03-17 Neurogen Corporation 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
JP4842929B2 (ja) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
US7507740B2 (en) * 2004-06-02 2009-03-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
ZA200610669B (en) * 2004-06-02 2008-06-25 Takeda Pharmaceutical Fused heterocyclic compound
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2441869C2 (ru) * 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
TWI392676B (zh) * 2005-12-21 2013-04-11 Abbott Lab 抗病毒化合物、其製備方法及用途
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101611041A (zh) 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN104311563B (zh) * 2007-11-28 2016-12-07 达那-法伯癌症研究所 Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
JP5813785B2 (ja) * 2011-02-04 2015-11-17 デュケイン ユニバーシティー オブ ザ ホリー スピリット 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2900671A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
CN104781260A (zh) 2012-09-26 2015-07-15 拜耳制药股份公司 用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
EP2925747B1 (en) * 2012-11-29 2020-06-24 Merck Patent GmbH Azaquinazoline carboxamide derivatives
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
RS63190B1 (sr) 2014-08-04 2022-06-30 Nuevolution As Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
RU2137762C1 (ru) 1994-02-23 1999-09-20 Пфайзер Инк. 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
DK0819129T3 (da) * 1995-04-03 2000-10-23 Novartis Ag Pyrazolderivater og fremgangsmåde til deres fremstilling
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AU5692298A (en) * 1996-11-26 1998-06-22 American Cyanamid Company Biaryl-pyridoquinazolinone derivatives as anti-cancer agents

Also Published As

Publication number Publication date
JP2000505109A (ja) 2000-04-25
AU4718997A (en) 1998-06-22
EP0946554A1 (en) 1999-10-06
CO4650037A1 (es) 1998-09-03
IL129825A0 (en) 2000-02-29
MA26452A1 (fr) 2004-12-20
AP9701146A0 (en) 1998-01-31
CA2272705A1 (en) 1998-06-04
PE17299A1 (es) 1999-02-19
US6413971B1 (en) 2002-07-02
NO992524D0 (no) 1999-05-26
CN1237177A (zh) 1999-12-01
BR9713552A (pt) 2000-01-25
NO992524L (no) 1999-05-26
ID18958A (id) 1998-05-28
WO1998023613A1 (en) 1998-06-04
OA11051A (en) 2003-03-07
CA2272705C (en) 2003-03-18
HRP970641A2 (en) 1998-10-31
AR010740A1 (es) 2000-07-12
KR20000057228A (ko) 2000-09-15
HN1997000146A (es) 1998-02-26
US20020045630A1 (en) 2002-04-18
IS5041A (is) 1999-04-30
PA8442001A1 (es) 2000-05-24
TNSN97192A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
BG103417A (bg) Кондензирани бициклични производни на пиримидина
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BG103947A (bg) Производни на 9-оксимеритромицин
BG103518A (bg) 2-(пурин-9-ил)-тетрахидрофуран-3,4-диолови производни
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
SE9702001D0 (sv) Novel compounds
MY119181A (en) Aryl pyrimidine derivatives
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
AP9701041A0 (en) Pyridylpyrrole compounds.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
AU1428801A (en) Novel (1,2,3)-triazolo(4,5-D)pyrimidine compounds
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
BG103260A (bg) Използване на 1-хидрокси-2-пиридони за лечение насебореен дерматит
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
YU46302A (sh) Supstituisani piroli
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
AU579196B2 (en) 4-Oxo-piridol(2,3-d)pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof